Yield10 Bioscience, Inc. Common Stock

YTEN

Valor de mercado US$ 1,85 mi

-Earns $1 million in milestone payments from Vision Bioenergy Oilseeds -Earns $1 million in milestone payments from Vision Bioenergy Oilseeds

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder's equity of at least $2,500,000. Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on May 16, 2024.

Biotech stocks are a tricky bunch, prone to wild moves and technical patterns that are tough to nail down.

WOBURN, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. The 1-for-24 reverse stock split will be effective as of 5:00 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on Thursday, May 2, 2024, and the Company's common stock will begin trading on a split-adjusted basis on Friday, May 3, 2024.

Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript

-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada -Management will host a conference call today at 4:30 p.m. (ET) to review  financial results and provide a corporate update

WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024.

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Office (“PBO”) of the Canadian Food Inspection Agency (“CFIA”) recently reviewed information on the Company's E3902 Camelina sativa (“Camelina”) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. Yield10's E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by five percent and produce a lighter seed coat color as compared to the parental Camelina line. E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.

Yield10 Bioscience (NASDAQ: YTEN ) stock is rocketing higher on Thursday after the agricultural bioscience company got new approval from the Department of Agriculture's (USDA) Biotechnology Regulatory Services (BRS). The big news here is Yield10 Bioscience's Camelina sativa varieties getting approval for breeding and growth in the U.S. This came after the agency determined the genetically modified plants don't fall under regulations 7 CFR part 340.

Yield10 Bioscience achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina in the United States.